Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Cisplatin + Etoposide
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cisplatin Platinol CDDP Chemotherapy - Platinum 7 Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).
Etoposide Vepesid EPEG|Eposin|VP-16|VP-16-213 TOPO2 inhibitor 5 Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01993810 Phase III Carboplatin + Pemetrexed Disodium Durvalumab Cisplatin + Etoposide Carboplatin + Paclitaxel Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer Active, not recruiting USA 0
NCT06172296 Phase III Cyclophosphamide + Topotecan Cisplatin + Etoposide Dinutuximab + Irinotecan + Temozolomide Cisplatin + Dinutuximab + Etoposide Dinutuximab beta + Temozolomide Cisplatin + Cyclophosphamide + Dexrazoxane + Dinutuximab + Doxorubicin + Etoposide + Topotecan + Vincristine Sulfate Dinutuximab + Isotretinoin Carboplatin + Cyclophosphamide + Etoposide + Melphalan + Thiotepa Cisplatin + Cyclophosphamide + Dexrazoxane + Doxorubicin + Etoposide + Topotecan + Vincristine Sulfate Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma Recruiting USA | CAN 0
NCT05566041 Phase III Cisplatin + Etoposide Carboplatin + Etoposide + RRx-001 Cisplatin + Etoposide + RRx-001 Carboplatin + Etoposide A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer (REPLATINUM) Recruiting USA 0
NCT03745222 Phase III Tislelizumab Cisplatin + Etoposide + Tislelizumab Carboplatin + Paclitaxel + Tislelizumab Cisplatin + Etoposide Carboplatin + Paclitaxel A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001) Terminated USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 13
NCT06333314 Phase II Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) Not yet recruiting FRA 0
NCT04602533 Phase II Cisplatin + Etoposide Durvalumab Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) Recruiting DEU 0
NCT04624204 Phase III Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) Recruiting USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 17
NCT03382561 Phase II Cisplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab Cisplatin + Etoposide Carboplatin + Etoposide Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer Active, not recruiting USA 0
NCT01642251 Phase Ib/II Cisplatin + Etoposide Veliparib Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer Completed USA 0
NCT03066778 Phase III Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Completed USA | NZL | GBR | FRA | ESP | DEU | CAN | AUS 11
NCT04092283 Phase III Carboplatin + Paclitaxel Cisplatin + Etoposide Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Paclitaxel Durvalumab Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Active, not recruiting USA 1
NCT05058651 Phase II Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung Recruiting USA 0
NCT01857934 Phase II Doxorubicin Sargramostim Aldesleukin Vincristine Sulfate Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan Therapy for Children With Advanced Stage Neuroblastoma Active, not recruiting USA 0
NCT02768558 Phase III Cisplatin + Etoposide Cisplatin + Etoposide + Nivolumab Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC Terminated USA 0
NCT03840902 Phase II Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Terminated USA | NLD | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT03811002 Phase II Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer Active, not recruiting USA 1
NCT01175356 Phase I Busulfan + Melphalan Cyclophosphamide + Topotecan 131I-MIBG Cyclophosphamide + Doxorubicin + Vincristine Sulfate Cisplatin + Etoposide Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Active, not recruiting USA 0
NCT02537418 Phase I Cisplatin + Etoposide Durvalumab Tremelimumab Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens Active, not recruiting CAN 0


Additional content available in CKB BOOST